NewAmsterdam Pharma Company NAMS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -953.6%-551pp | -1,002.9%-616pp | -575.8%-27.7pp | -270%+2,541pp | -402.5%+2,492pp | |
| Net margin | -942.8%-545pp | -905.7%-375pp | -627.3%-35.2pp | -258.9%+2,831pp | -397.5%+2,935pp | |
| EBITDA margin | -952.6%-550pp | -1,001.9%-615pp | -575.2%-27.3pp | -269.7%+2,540pp | -402.2%+2,491pp | |
| Free cash flow margin | -630.1%-332pp | -657.8%-308pp | -410.1%+50.8pp | -194.2%+2,355pp | -298.5%+2,097pp | |
| Returns | ||||||
| Return on equity | -29.5%+2.0pp | -28.3%+17.9pp | -39.9%+16.0pp | -28.4%+31.9pp | -31.5%+24.9pp | |
| Return on assets | -27.4%+1.2pp | -24.9%+14.9pp | -36.1%— | -26.3%— | -28.7%— | |
| Return on invested capital | -181.6%— | —— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0.1×— | 0.1×— | 0.1×— | |
| Liquidity | ||||||
| Current ratio | 9.8×-10.2× | 7.9×-0.2× | 12.6×+2.0× | 21.1×+11.3× | 20×+11.8× | |
| Quick ratio | 9.8×-10.2× | 7.9×-0.2× | 12.6×+2.0× | 21.1×+11.3× | 20×+11.8× | |
| Cash ratio | 6.8×-11.5× | 5.7×-1.5× | 9.2×-1.0× | 15.4×+5.9× | 18.3×+10.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Valuation | ||||||
| Market capitalization | $3.68B+63.7% | $3.98B+44.6% | $3.2B+114% | $2.07B+19.5% | $2.25B+5.6% | |
| Enterprise value | $3.22B+115% | $3.49B+76.2% | $2.67B+149% | $1.5B+15.7% | $1.5B-8.9% | |
| Price / sales | 163.1×+115× | 176.8×+116× | 90.9×+46.4× | 32.3×-201× | 47.7×-262× | |
| Price / book | 5.5×+2.6× | 5.8×+2.2× | 4.4×+0.5× | 2.7×-1.8× | 2.9×-2.3× | |
| EV / sales | 142.8×+111× | 155×+112× | 75.6×+43.7× | 23.5×-151× | 31.8×-208× | |
| Free cash flow yield | -3.9%+2.4pp | -3.7%+2.1pp | -4.5%+5.9pp | -6%+4.9pp | -6.3%+1.5pp | |
| Earnings yield | -5.8%+2.6pp | -5.1%+3.7pp | -6.9%+6.4pp | -8%+5.2pp | -8.3%+2.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do NewAmsterdam Pharma Company's ratios come from?
- Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.